Chronic migraine is a burdensome condition, and onabotulinumtoxinA is revealed to be an effective therapy. Migraine shows a bidirectional relationship with sleep, but the effects of preventive therapies on sleep quality are poorly studied. This study aims to evaluate the effects of a single session of onabotulinumtoxinA on patients' sleep quality and correlates the results with measures of comorbid anxiety/depression. Patients completed self-administrable questionnaires about sleep quality (Pittsburgh Sleep Quality Index-PSQI) and psychological symptoms (Beck Depression Inventory, 2nd edition-BDI-II-and Hospital Anxiety and Depression Scale-HADS-subscales "a" and "d" for anxiety and depression, respectively), and reported migraine frequency at baseline and after 12 weeks. The 42 included patients showed a significant reduction in migraine days (from 20.6 +/- 6.0 to 13.6 +/- 6.2, p < 0.001), while no changes were observed in sleep quality (PSQI score from 11.0 +/- 5.0 to 9.8 +/- 4.6, p = 0.277) or psychological measures (BDI-II from 16.7 +/- 10.2 to 15.7 +/- 10.3, p = 0.678; HADS-a from 10.3 +/- 4.8 to 9.3 +/- 5.5, p = 0.492; and HADS-d from 7.2 +/- 3.9 to 7.1 +/- 5.0, p = 0.901). On the other hand, a strong correlation among PSQI, BDI-II, HADS-a, and HADS-d scores (p < 0.001, rho > 0.7) was found. Despite its efficacy in migraine prevention, a single session of onabotulinumtoxinA was not able to affect patients' sleep quality or their psychological symptoms.

Torrente, A., Alonge, P., Pilati, L., Gagliardo, A., Vassallo, L., Di Stefano, V., et al. (2023). Effects of a Single Session of OnabotulinumtoxinA Therapy on Sleep Quality and Psychological Measures: Preliminary Findings in a Population of Chronic Migraineurs. TOXINS, 15(9), 1-12 [10.3390/toxins15090527].

Effects of a Single Session of OnabotulinumtoxinA Therapy on Sleep Quality and Psychological Measures: Preliminary Findings in a Population of Chronic Migraineurs

Torrente, Angelo;Alonge, Paolo;Pilati, Laura;Gagliardo, Andrea;Vassallo, Lavinia;Di Stefano, Vincenzo;Lupica, Antonino;Quartana, Irene;Camarda, Cecilia;Brighina, Filippo
2023-08-27

Abstract

Chronic migraine is a burdensome condition, and onabotulinumtoxinA is revealed to be an effective therapy. Migraine shows a bidirectional relationship with sleep, but the effects of preventive therapies on sleep quality are poorly studied. This study aims to evaluate the effects of a single session of onabotulinumtoxinA on patients' sleep quality and correlates the results with measures of comorbid anxiety/depression. Patients completed self-administrable questionnaires about sleep quality (Pittsburgh Sleep Quality Index-PSQI) and psychological symptoms (Beck Depression Inventory, 2nd edition-BDI-II-and Hospital Anxiety and Depression Scale-HADS-subscales "a" and "d" for anxiety and depression, respectively), and reported migraine frequency at baseline and after 12 weeks. The 42 included patients showed a significant reduction in migraine days (from 20.6 +/- 6.0 to 13.6 +/- 6.2, p < 0.001), while no changes were observed in sleep quality (PSQI score from 11.0 +/- 5.0 to 9.8 +/- 4.6, p = 0.277) or psychological measures (BDI-II from 16.7 +/- 10.2 to 15.7 +/- 10.3, p = 0.678; HADS-a from 10.3 +/- 4.8 to 9.3 +/- 5.5, p = 0.492; and HADS-d from 7.2 +/- 3.9 to 7.1 +/- 5.0, p = 0.901). On the other hand, a strong correlation among PSQI, BDI-II, HADS-a, and HADS-d scores (p < 0.001, rho > 0.7) was found. Despite its efficacy in migraine prevention, a single session of onabotulinumtoxinA was not able to affect patients' sleep quality or their psychological symptoms.
27-ago-2023
Torrente, A., Alonge, P., Pilati, L., Gagliardo, A., Vassallo, L., Di Stefano, V., et al. (2023). Effects of a Single Session of OnabotulinumtoxinA Therapy on Sleep Quality and Psychological Measures: Preliminary Findings in a Population of Chronic Migraineurs. TOXINS, 15(9), 1-12 [10.3390/toxins15090527].
File in questo prodotto:
File Dimensione Formato  
toxins-15-00527.pdf

accesso aperto

Descrizione: Effect of botulinum toxin on sleep quality in migraine
Tipologia: Versione Editoriale
Dimensione 902.83 kB
Formato Adobe PDF
902.83 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/635213
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact